Non-alcoholic fatty liver disease from the point of view of diabetologist

Czech version

Authors: Vladimír Uličiansky
Authors‘ workplace: Via medica, s. r. o., Košice
Published in: Diab Obez 2020; 20(39): 16-20
Category:

Overview

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries. It is characterized by insulin resistance and hepatic triglyceride accumulation in the absence of co-existing etiologies (excessive alcohol consumption, viral hepatitis, medications or other etiologies for hepatic steatosis). Risk factors for the development of NAFLD include obesity, diabetes mellitus type 2, dyslipoproteinemia. Author reviews the clinical picture, diagnosis and treatment of NAFLD from the point of view of diabetologist.

Keywords:

treatment – diabetes mellitus type 2 – diagnostic – non-alcoholic fatty liver disease

Sources

Holomáň J, Szántová M, Zima M et al. Manažment nealkoholovej tukovej choroby pečene. Via Pract 2016; 13(5): 179–186.
Lazúrová I, Fraenkel E, Dravecká I. Nealkoholová steatóza pečene (NAFLD) a inzulínová senzitivita. Čes a Slov Gastroent a Hepatol 2007; 61(4): 229–232.
Zima M. Nealkoholová tuková choroba pečene. Via Pract 2008; 5(4/5): 166–169.
Younossi Z, Tacke F, Arrese M et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019; 69(6): 2672–2682. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.30251>.
Rác M. Diabezita a nealkoholová tuková choroba pečene. In: Fábryová Ľ, Holéczy P et al. Diabezita. Diabetes a obezita nerozlučné dvojičky. Facta Medica: Brno 2019: 246–259. ISBN 978–80–88056–09–6.
Szántová M. Aktuálny diagnostický prístup k cirhóze a portálnej hypertenzii. Rizikové faktory cirhózy – dá a má sa u jedinca cirhóza predpokladať a cielene hľadať? Gastroenterol Prax 2015; 14(1): 10–17.
Janíčko M, Veselíny E, Jarčuška P. Chronicky zvýšená aktivita pečeňových testov. Gastroent Hepatol 2016; 70(2): 110–117.
Belovičová M, Mašterová V. Nealkoholová tuková choroba pečene – závažná komorbidita diabezity. Forum Diab 2016; 5(1): 45–48.
Matthews DR.HOMA-IR calculator. Dostupné z WWW: <https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance>.
Akshintala D, Chugh R, Amer F et al. Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes. Dostupné z WWW: https://www.ncbi.nlm.gov/books/NBK544043. Last Update: July 9, 2019.
Brůha R, Dvořák K, Fejfar T et al. Doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu nealkoholové tukové choroby jater (NAFLD). Dostupné z WWW: <https://www.ces-hep.cz/file/601/nafld-dop-postup-chs.pdf>.
Chalasani N, Younossi Z, Lavine JE et al.The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328–357. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.29367>.
EASL-EAS-EASO Clinical Practice Guidelines: for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6):1388–1402. <http://dx.doi.org/10.1016/j.jhep.2015.11.004>.
Dostupné z WWW: <https://nafldscore.com/>.
LaBrecque DR, Abbas Z, Anania F et al. [Review Team]. World Gastroenterology Organisation Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Review. Clin Gastroenterol 2014; 48(6): 467–473. Dostupné z DOI: <http://dx.doi.org/10.1097/MCG.0000000000000116>.
Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387(10019): 679–690. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00803-X>.
Shimizu M, Suzuki K, Kato K et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019; 21(2): 285–292. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13520>.
Xiang Z, Chen YP, Ma KF et al. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review BMC Gastroenterol 2013; 13: 140. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–230X-13–140>.
Holomáň J, Borecký P, Lietava J. Účinnosť a bezpečnosť silymarínu u pacientov s chronickými chorobami pečene – multicentrická, prospektívna, otvorená klinická štúdia IMHOTEP. Gastroent Hepatol 2014; 68(4): 346–355. Dostupné z WWW: <http://www.csgh.info/en/article/efficiency-and-safety-of-silymarine-in-patients-with-chronic-liver-diseases-multicenter-prospective-open-clinical-trial-imhotep-892>.
Leoni S, Tovoli F, Napoli L et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361–3373. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v24.i30.3361>.
Chopra S, Lai M, Lindor KD et al. [Review Team]. Management of nonalcoholic fatty liver disease in adults. Dostupné z WWW: <https://www.uptodate.com/contents/management-of-nonalcoholic-fatty-liver-disease-in-adultsLast>. [24–06–2019].
Prídavková D, Sváková V, Galajda P et al. Moderné trendy v liečbe diabetes mellitus u pacientov s hepatopatiami. Forum Diab 2019; 8(2): 133–137.